What is the role of bortezomib in the treatment of thrombotic thrombocytopenic purpura (TTP)?

Updated: May 25, 2021
  • Author: Theodore Wun, MD, FACP; Chief Editor: Srikanth Nagalla, MD, MS, FACP  more...
  • Print

Patriquin et al reported successful use of the proteasome inhibitor bortezomib in patients with TTP refractory to intensive therapy. Five of the six patients in this study achieved complete remission with bortezomib; one died of cardiac arrest due to underlying disease. No treatment-related adverse events were observed. [26]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!